Why has Align Technology lagged the market?

Align Technology stock has failed to keep pace with the broader market over the past 12 months for the global medical device company, which has a market capitalization of about $11.4 billion. Best known for its Invisalign clear aligners, Vivera retainers and iTero intraoral scanners, the company provides digital orthodontic and restorative solutions in the United States, Switzerland and other international markets.

Over the past 52 weeks, the stock has risen by about 12%, while the S&P 500 gained 18.7% in the same period. Year to date, ALGN shares are up 1.8%, compared with a 12.1% increase in the S&P 500. The stock has also trailed the State Street Health Care Select Sector SPDR ETF (XLV), which has climbed 25.8% over the past year.

What is behind the selling pressure?

Weakness in clear aligner demand in North America, rising competition and concerns about market-share erosion have weighed on the stock’s relative performance. Softness in the iTero scanning business, valuation concerns and uncertainty around a European Union antitrust probe have also pressured investor sentiment.

What are analysts expecting, and what do the price targets say?

Among the 16 analysts covering the stock on Wall Street, the consensus view is now moderate buy. That breakdown includes 10 strong buy ratings, five hold ratings and one moderate sell recommendation. Three months ago, there were nine strong buy ratings, suggesting the outlook has become slightly more positive.

On August 19, Piper Sandler analyst Jason Bednar reiterated his buy rating on the stock and kept his target price at $235. The average analyst target stands at $207.07, about 30.1% above the current price. The highest target of $240 points to upside potential of 50.8%.

Profit outlook and recent earnings performance

For the fiscal year ending in December 2026, adjusted earnings per share are expected to rise 10.9% year over year to $9.38. The company’s results over the past four quarters have been mixed, with three periods beating market expectations and one falling short.

  • 52-week share return: about 12%
  • Average analyst price target: $207.07
  • FY2026 adjusted EPS estimate: $9.38